Cargando…

Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates

To prevent important infectious diseases such as tuberculosis, malaria and HIV, vaccines inducing greater T cell responses are required. In this study, we investigated whether fusion of the M. tuberculosis antigen 85A to recently described adjuvant IMX313, a hybrid avian C4bp oligomerization domain,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spencer, Alexandra J., Hill, Fergal, Honeycutt, Jared D., Cottingham, Matthew G., Bregu, Migena, Rollier, Christine S., Furze, Julie, Draper, Simon J., Søgaard, Karen C., Gilbert, Sarah C., Wyllie, David H., Hill, Adrian V. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314664/ https://www.ncbi.nlm.nih.gov/pubmed/22470455 http://dx.doi.org/10.1371/journal.pone.0033555

Ejemplares similares

Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
por: Rollier, Christine S., et al.
Publicado: (2020)

4-1BBL Enhances CD8(+) T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques
por: Spencer, Alexandra J., et al.
Publicado: (2014)

Accelerating vaccine development and deployment: report of a Royal Society satellite meeting
por: Bregu, Migena, et al.
Publicado: (2011)

Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8(+) T Cell Responses
por: Halbroth, Benedict R., et al.
Publicado: (2018)

Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen
por: Wyllie, David H., et al.
Publicado: (2012)

Enhanced Vaccine-Induced CD8(+) T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain
por: Spencer, Alexandra J., et al.
Publicado: (2014)

T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein
por: Forbes, Emily K., et al.
Publicado: (2012)

Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
por: Betts, Gareth, et al.
Publicado: (2012)

Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles
por: Daniels-Treffandier, Helene, et al.
Publicado: (2016)

Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2008)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
por: Brookes, Roger H., et al.
Publicado: (2011)

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
por: Warimwe, George M, et al.
Publicado: (2013)

Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2008)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
por: Cottingham, Matthew G., et al.
Publicado: (2011)

Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection
por: Xu, Zheng Zhong, et al.
Publicado: (2016)

MRI Based Localisation and Quantification of Abscesses following Experimental S. aureus Intravenous Challenge: Application to Vaccine Evaluation
por: Allen, Elizabeth R., et al.
Publicado: (2016)

Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
por: Collins, Katharine A., et al.
Publicado: (2017)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
por: Dicks, Matthew D. J., et al.
Publicado: (2012)

Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen
por: Favrot, Lorenza, et al.
Publicado: (2013)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
por: Dicks, Matthew D. J., et al.
Publicado: (2015)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Expression of recombinant Mycobacterium bovis antigen 85B by Mycobacterium smegmatis mc(2)
por: Soares, Amanda, et al.
Publicado: (2014)

Immunogenicity and Protective Efficacy of a Novel Recombinant BCG Strain Overexpressing Antigens Ag85A and Ag85B
por: Wang, Chun, et al.
Publicado: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
por: Pathan, Ansar A., et al.
Publicado: (2012)

Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1
por: Biswas, Sumi, et al.
Publicado: (2011)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
por: Li, Yuanyuan, et al.
Publicado: (2016)

Human T Cell and Antibody-Mediated Responses to the Mycobacterium tuberculosis Recombinant 85A, 85B, and ESAT-6 Antigens
por: Macedo, Gilson C., et al.
Publicado: (2011)

Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
por: Reyes-Sandoval, Arturo, et al.
Publicado: (2012)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial
por: Rowland, Rosalind, et al.
Publicado: (2013)

Immunogenicity of a Fusion Protein Containing Immunodominant Epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in Mice and Active TB Infection
por: de Sousa, Eduardo Martins, et al.
Publicado: (2012)

Novel human recombinant antibodies against Mycobacterium tuberculosis antigen 85B
por: Fuchs, Manon, et al.
Publicado: (2014)

EXPRESSION OF IMMUNOGLOBULIN, GRANZYME-B AND PERFORIN AGAINST Ag85A AND Ag85B PROTEINS OF MYCOBACTERIUM TUBERCULOSIS IN BALB/C MICE
por: Fihiruddin,, et al.
Publicado: (2019)

Correction: Immunogenicity of a Fusion Protein Containing Immunodominant Epitopes of Ag85C, MPT51, and HspX from Mycobacterium tuberculosis in Mice and Active TB Infection
por: de Sousa, Eduardo Martins, et al.
Publicado: (2013)

Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A
por: Griffiths, Kristin L., et al.
Publicado: (2011)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
por: Minassian, Angela M, et al.
Publicado: (2011)

Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A
por: Beverley, Peter, et al.
Publicado: (2013)

Ag85-focused T-cell immune response controls Mycobacterium avium chronic infection
por: Cerqueira-Rodrigues, Bruno, et al.
Publicado: (2018)

STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines
por: Padron-Regalado, Eriko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vobd5uckcv4ln8lsbp9jvp634e